Skin Infections, Bacterial
8
0
0
8
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
50%
4 trials in Phase 3/4
50%
4 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (8)
GSK1322322 Versus Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infection
Retapamulin Microdialysis Feasibility Study
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
Topical SB-275833 Ointment, 1% For The Treatment Of Impetigo
Pharmacokinetics of Retapamulin in Pediatric Subjects With Uncomplicated Skin Infections.
Retapamulin Versus Placebo in Secondarily-Infected Traumatic Lesions (SITL)
ALTARGO(Retapamulin) PMS(Post-marketing Surveillance)
United States Pharmacovigilence Retapamulin-Prescribing